Excelsior Biopharma

Excelsior Biopharma FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Excelsior Biopharma (6496.TWO) as of Oct 28, 2026 is 95.91 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 361.63 % — a change of -73.48% (lower).

FCF Conversion

95.91 %

YoY

-73.48%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Excelsior Biopharma is 2025 95.91 % . FCF Conversion Rate (FCF/EBITDA) of Excelsior Biopharma was 2024 361.63 % . It decreases by -73.48% lower compared to the previous year.

The Excelsior Biopharma FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
52.91 TWD
Jan 1, 2019
-267.72 TWD
Jan 1, 2020
1,442.49 TWD
Jan 1, 2021
-338.33 TWD
Jan 1, 2022
6.80 TWD
Jan 1, 2023
187.24 TWD
Jan 1, 2024
361.63 TWD
Jan 1, 2025
95.91 TWD
The Excelsior Biopharma FCF Conversion history
YEARFCF ConversionYoY
95.91 %-73.48%
361.63 %+93.14%
187.24 %+2,651.67%
6.80 %-102.01%
-338.33 %-123.45%
1,442.49 %-638.81%
-267.72 %-605.95%
52.91 %-55.34%
118.48 %+20.12%
98.64 %+5,715.03%
1.70 %-97.62%
71.34 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Excelsior Biopharma Stock analysis

What does Excelsior Biopharma do? Excelsior Biopharma Inc., headquartered in Taipei City, Taiwan, operates in the Health Care sector. The company focuses on the research, development, manufacturing, and distribution of pharmaceutical products, including prescription and non-prescription drugs, health care products, medical equipment, and rapid test reagents. Listed on 19 December 2014, Excelsior Biopharma serves both domestic and international markets with its diverse product portfolio. Excelsior Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Excelsior Biopharma stock

FCF Conversion Rate (FCF/EBITDA) of Excelsior Biopharma is 95.91 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Excelsior Biopharma changed from 361.63 % to 95.91 %, representing a -73.48% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Excelsior Biopharma since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Excelsior Biopharma with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Excelsior Biopharma

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Excelsior Biopharma